Home » Novel Preclinical Drug Could Have Potential to Combat Depression, Brain Injury, and Cognitive Disorders

Novel Preclinical Drug Could Have Potential to Combat Depression, Brain Injury, and Cognitive Disorders

This shows the outline of a head.

A preclinical drug that inhibits the kinase enzyme Cdk5 may have the potential to treat depression, brain injuries, and disorders associated with cognitive impairment.

Source: University of Alabama Birmingham

James Bibb, Ph.D., and colleagues have described a novel preclinical drug that could have the potential to combat depression, brain injury and diseases that impair cognition. The drug, which notably is brain-permeable, acts to inhibit the kinase enzyme Cdk5.

Cdk5 is a crucial regulator of signaling in brain neurons. Over three decades of study, it has … Read the full article in the Neuroscience news by clicking the image above.

Please follow share and like me:

Leave a reply